about
Targeting New Candidate Genes by Small Molecules Approaching Neurodegenerative DiseasesMotor Dysfunctions and Neuropathology in Mouse Models of Spinocerebellar Ataxia Type 2: A Comprehensive ReviewDNA secondary structure at chromosomal fragile sites in human disease.BAG2 structure, function and involvement in disease.An Exploration of the Universe of Polyglutamine Structures.PolyQ 2.0: an improved version of PolyQ, a database of human polyglutamine proteinsVariation and Evolution in the Glutamine-Rich Repeat Region of Drosophila Argonaute-2.Mutant CAG Repeats Effectively Targeted by RNA Interference in SCA7 Cells.Determination of Genotypic and Phenotypic Characteristics of Friedreich's Ataxia and Autosomal Dominant Spinocerebellar Ataxia Types 1, 2, 3, and 6Current proceedings of cerebral palsy.The FOXP2-Driven Network in Developmental Disorders and NeurodegenerationStructure and Dynamics of RNA Repeat Expansions That Cause Huntington's Disease and Myotonic Dystrophy Type 1.Structures of RNA repeats associated with neurological diseases.Cerebellum-from J. E. Purkyně up to Contemporary Research.Nanoparticulate strategies for the treatment of polyglutamine diseases by halting the protein aggregation process.Proteins Containing Expanded Polyglutamine Tracts and Neurodegenerative Disease.Candida albicans Is Resistant to Polyglutamine Aggregation and ToxicityLarge normal-range TBP and ATXN7 CAG repeat lengths are associated with increased lifetime risk of depression.Kennedy disease with difficulty in differential diagnosis: A case report.Therapeutic implication of autophagy in neurodegenerative diseases.A peptidylic inhibitor for neutralizing expanded CAG RNA-induced nucleolar stress in polyglutamine diseases.Design and Synthesis of Cyclic Mismatch-Binding Ligands (CMBLs) with Variable Linkers by Ring-Closing Metathesis and their Photophysical and DNA Repeat Binding Properties.Glutamine Codon Usage and polyQ Evolution in Primates Depend on the Q Stretch Length.Comparative Analysis of Mutant Huntingtin Binding Partners in Yeast Species.The Role of Gene Editing in Neurodegenerative Diseases.
P2860
Q26771812-EEC34977-B88C-4ECE-99F1-E6DF5D8F6856Q28076174-77DF837F-C4EC-434C-9C9D-B820D68968E2Q30300009-2655702C-69D5-4CB4-92BD-3AFAA1862CA3Q33634944-F6715587-6FFC-4B41-83B3-E426A9D74859Q35818532-DCE6DA74-94D7-4D24-A439-04E54DDD15BCQ36688900-467AC781-7CEF-49C2-BFF1-C5BBC1188E4FQ37163048-CEA812F7-860F-40D3-9D12-A15E637DBE96Q37539531-C0632D87-4F52-44D2-A9ED-7B783FE43F9CQ37703698-8BF22824-E5CA-4186-ACFA-34EB3A62DD54Q38364327-4D77B301-31EE-4087-8F6A-DD6887ED07DEQ38430007-3B0AC176-2B44-4B16-BB12-8738BA1147B7Q38430517-128F97B0-A1BE-4F5D-B433-90B947CA74D0Q38994216-58D00688-9273-498D-89B0-8892BB838F6CQ39011791-1C4426BA-0102-44C8-9013-4C7E4A49E83AQ39112084-00BAA2A4-BF17-4F39-85DD-3DCA98712B1AQ39124557-8AE18E11-08E2-4B6B-BE0C-361DE32798B4Q39222757-CDC67419-5A46-4000-A886-9AFCE1B17512Q41173141-31FD44E7-A072-4F36-9E26-EE9AB92C2798Q42273018-7EC7768A-A872-4594-9D55-913859009215Q42353908-AB0D0DB3-69E5-48FE-86EA-44F589B6BB84Q47236927-D45DFCBF-33CC-43DD-947B-C5F0D852CFF6Q53583446-F642DB31-33EB-47F0-B83A-9FE920978B0EQ55042053-6EE74906-C812-4DCC-A86F-6EFBD04D30DCQ55498681-E6731203-FE66-4297-A584-C0A6AC2D1841Q55709239-C9246E33-F16A-464A-8CD3-1773A52AE76A
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Polyglutamine (PolyQ) diseases: genetics to treatments.
@en
type
label
Polyglutamine (PolyQ) diseases: genetics to treatments.
@en
prefLabel
Polyglutamine (PolyQ) diseases: genetics to treatments.
@en
P2093
P2860
P356
P1433
P1476
Polyglutamine (PolyQ) diseases: genetics to treatments
@en
P2093
Ching-Shiang Chi
Giia-Sheun Peng
Horng-Jyh Harn
Hueng-Chuen Fan
Shinn-Zong Lin
Shyi-Jou Chen
P2860
P304
P356
10.3727/096368914X678454
P50
P577
2014-01-01T00:00:00Z